AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations SAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting...

AXIM® Biotechnologies Begins Clinical Trials on Its ImmunoPass Rapid Diagnostic Test With Vaccine Recipients SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological...

New Research Details How B2B Content Marketers are Responding to COVID-19 NEW YORK, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Content Marketing Institute (CMI) just released its 11th annual B2B content marketing research report which includes insights into how content marketers...

Multiverse Investment Fund Announces Portfolio Company’s Participation in Coronavirus Vaccine Development LOS ANGELES, June 09, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- Multiverse Investment Fund I, LP, a private venture capital fund dedicated to long-term capital investment in companies offering...

Multiverse Investment Fund Announces Portfolio Company’s Commencement of Clinical Trials to Treat Acute Respiratory Distress Syndrome (ARDS) Caused by Coronavirus (COVID-19) Multiverse Investment Fund Portfolio Company Begins Clinical Trials to Treat Acute Respiratory Distress Syndrome (ARDS) Caused by Coronavirus (COVID-19) ARDS has been identified as the leading cause...